Clough Capital Partners’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History

Clough Capital Partners’s Portfolio KDNY Stock Details KDNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-59,780	Closed	-$3.21M	–	169
2017 Q1	$3.21M	Sell	59,780 -5,500	-8%	-$311K	0.2%	81
2016 Q4	$3.72M	Buy	65,280 +6,840	+12%	+$414K	0.25%	93
2016 Q3	$3.63M	Buy	+58,440	New	+$4.13M	0.19%	112
2016 Q2	–	Sell	-59,627	Closed	-$3.82M	–	246
2016 Q1	$3.82M	Buy	59,627 +8,060	+16%	+$652K	0.18%	119
2015 Q4	$7.26M	Sell	51,567 -66,972	-56%	-$9.1M	0.34%	90
2015 Q3	$11.5M	Buy	118,539 +6,660	+6%	+$793K	0.5%	65
2015 Q2	$17M	Buy	+111,879	New	+$18.5M	0.65%	56

Other funds holding KDNY

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ORI

Oak Ridge Investments Chicago, Illinois $1.77B AUM 63.16% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Clough Capital Partners's KDNY Position: Q2 2017 in Review

Clough Capital Partners sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q2 2017, closing a stake of 59,780 shares — an estimated $3.21M sold.

Clough Capital Partners first reported a position in KDNY in Q2 2015 and held it in 7 quarters. The position peaked at $17M in Q2 2015. 82 funds tracked by Wall St. Rank hold KDNY as of Q2 2017.

Clough Capital Partners reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q2 2017 after selling out during the quarter.
Clough Capital Partners sold 59,780 Chinook Therapeutics, Inc. Common Stock shares in Q2 2017, an estimated $3.21M.
Clough Capital Partners first reported a position in Chinook Therapeutics, Inc. Common Stock in Q2 2015 and held it in 7 quarters.
Clough Capital Partners's Chinook Therapeutics, Inc. Common Stock position peaked at $17M in Q2 2015.
82 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q2 2017.

Based on Clough Capital Partners's 13F filing for Q2 2017, filed 14 Aug 2017.